Neurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 39.5%, EPS grew 31.2% and free cash flow grew 43.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.
Follow NBIX
Neurocrine Biosciences, Inc. (NBIX) EV/Sales
As of 16 October 2026, Neurocrine Biosciences, Inc. (NBIX) trades at a EV/Sales of 4.1×. Over the past ten years it has ranged from 0.0× (March 2015) to 208× (November 2015); the current reading is higher than 3% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.6× | (17.64%) |
| FY2024 | 5.6× | (14.77%) |
| FY2023 | 6.6× | (11.07%) |
| FY2022 | 7.4× | 3.78% |
| FY2021 | 7.1× | (15.67%) |
| FY2020 | 8.4× | (31.07%) |
| FY2019 | 12.2× | (15.84%) |
| FY2018 | 14.5× | (62.44%) |
| FY2017 | 38.7× | (53.94%) |
| FY2016 | 84.1× | (58.07%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.1× | 26.66% |
| Mar 2026 | 4.0× | (12.75%) |
| Dec 2025 | 4.6× | (7.67%) |
| Sep 2025 | 5.0× | 4.23% |
| 35 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VTRS Viatris Inc. compare | 2.3× |
| HIMS Hims & Hers Health, Inc. compare | 2.7× |
| RDY Dr. Reddy's Laboratories Ltd compare | 2.9× |
| ELAN Elanco Animal Health Incorporated compare | 3.0× |
| NBIX Neurocrine Biosciences, Inc. | 4.1× |
| LNTH Lantheus Holdings, Inc. compare | 4.2× |
| ALKS Alkermes plc compare | 4.6× |
| UTHR United Therapeutics Corporation compare | 6.5× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 6.6× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)